XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.

Vaccination 105

Vaccination Vaccine Development Hormones 105

XTalks

JANUARY 20, 2021

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments).

Immune Response 52

Immune Response Research Allergies Protein 52

XTalks

JULY 25, 2023

Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. The non-inferiority of Cyfendus to BioThrax was statistically determined in the clinical study results. What Is Anthrax? Additionally, at Day 64, 86.6

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

The Pharma Data

MARCH 21, 2022

Years of toil in the laboratory have revealed how a marine bacterium makes a potent anti-cancer molecule. The anti-cancer molecule salinosporamide A, also called Marizomb, is in Phase III clinical trials to treat glioblastoma, a brain cancer. That was surprising,” she said.

Bacterium 52

Bacterium Scientist Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 2, 2022

Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. About Pneumococcal disease.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MAY 31, 2022

Affinivax’s most advanced vaccine candidate (AFX3772) includes 24 pneumococcal polysaccharides plus two conserved pneumococcal proteins (compared to up to 20 serotypes in currently approved vaccines). A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. Phase III is expected to start in the short term.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52